The method triggers immune responses that inhibit melanoma, triple-negative breast cancer, lung carcinoma, and ovarian cancer ...

In an early-stage clinical trial, the therapy nearly doubled the expected survival time of young patients. Still, experts ...

Some recommend scoring solid intraductal carcinoma as Gleason 5, but the cancer is linked to significantly poorer outcomes.

RXRX's CDK7 inhibitor REC-617 has demonstrated activity, but additional data from the ELUCIDATE trial in various solid tumors ...

Bristol Myers Squibb Receives Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo® (nivolumab) Across Multiple Solid Tumor Indications ...

The researchers called for further study to understand the mechanism of the relationship between obesity and ICI outcomes.

The fourth pair of denosumab biosimilars, Conexxence and Bomyntra, are expected to launch in the United States in mid 2025, ...

Dr. Hadiyah-Nicole Green has developed a novel cancer-killing technology, Laser-Activated NanoTherapy (LANT), that is of high ...

Research and Development (“R&D”) Expenses : R&D expenses for the three months ended December 31, 2024, were $8.2 million, compared to $13.5 million for the same period in 2023. The decrease was due ...

Generative Phosphoproteomics AP3 platform designed to enable streamlined, rational drug discovery, with proprietary, proteome-wide SAR delivering ...

Servier announces a strategic worldwide licensing agreement for Black Diamond Therapeutics' BDTX-4933 for solid tumors for an ...